{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:43:41Z","timestamp":1740149021166,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017555","name":"Catalyst Biosciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017555","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s12325-023-02570-6","type":"journal-article","created":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T10:01:40Z","timestamp":1687341700000},"page":"3739-3750","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia\u00a0B Patients"],"prefix":"10.1007","volume":"40","author":[{"given":"Alan","family":"Faraj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natacha","family":"Le Moan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduard","family":"Gorina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grant E.","family":"Blouse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3424-9686","authenticated-orcid":false,"given":"Ulrika S. H.","family":"Simonsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"key":"2570_CR1","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","volume":"344","author":"PM Mannucci","year":"2001","unstructured":"Mannucci PM, Tuddenham EGD. The hemophilias\u2014from royal genes to gene therapy. N Engl J Med. 2001;344:1773\u20139.","journal-title":"N Engl J Med"},{"key":"2570_CR2","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","volume":"19","author":"A Srivastava","year":"2013","unstructured":"Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19:e1\u201347.","journal-title":"Haemophilia"},{"key":"2570_CR3","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3324\/haematol.2019.232132","volume":"105","author":"PM Mannucci","year":"2020","unstructured":"Mannucci PM. Hemophilia therapy: the future has begun. Haematologica. 2020;105:545\u201353.","journal-title":"Haematologica"},{"key":"2570_CR4","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1111\/jth.15259","volume":"19","author":"CW You","year":"2021","unstructured":"You CW, Hong S-B, Kim S, et al. Safety, pharmacokinetics, and pharmacodynamics of a next-generation subcutaneously administered coagulation factor\u00a0IX variant, dalcinonacog alfa, in previously treated hemophilia\u00a0B patients. J Thromb Haemost. 2021;19:967\u201375.","journal-title":"J Thromb Haemost"},{"key":"2570_CR5","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/hae.14315","volume":"27","author":"J Mahlangu","year":"2021","unstructured":"Mahlangu J, Levy H, Lee M, Del Greco F. Efficacy and safety of subcutaneous prophylaxis with dalcinonacog alfa in adults with haemophilia\u00a0B. Haemophilia. 2021;27:574\u201380.","journal-title":"Haemophilia"},{"key":"2570_CR6","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1111\/jth.12672","volume":"12","author":"VS Blanchette","year":"2014","unstructured":"Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12:1935\u20139.","journal-title":"J Thromb Haemost"},{"key":"2570_CR7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1542\/pir.34.7.289","volume":"34","author":"B Zimmerman","year":"2013","unstructured":"Zimmerman B, Valentino LA. Hemophilia: in review. Pediatr Rev. 2013;34:289\u201394 (quiz 295).","journal-title":"Pediatr Rev"},{"key":"2570_CR8","unstructured":"Center for Biologics Evaluation and Research. Human gene therapy for hemophilia. US Food and Drug Administration. 2002. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/human-gene-therapy-hemophilia. Accessed 21 June 2023."},{"key":"2570_CR9","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1111\/cts.12794","volume":"13","author":"C Keipert","year":"2020","unstructured":"Keipert C, M\u00fcller-Olling M, Gauly F, Arras-Reiter C, Hilger A. Annual bleeding rates: pitfalls of clinical trial outcomes in hemophilia patients. Clin Transl Sci. 2020;13:1127\u201336.","journal-title":"Clin Transl Sci"},{"key":"2570_CR10","unstructured":"European Medicines Agency (2018) EMA Clinical investigation of recombinant and human plasma-derived factor IX products\u2014Scientific guideline. https:\/\/www.ema.europa.eu\/en\/clinical-investigation-recombinant-human-plasma-derived-factor-ix-products-scientific-guideline."},{"key":"2570_CR11","unstructured":"Center for Drug Evaluation, Research\nCenter for Biologics Evaluation and Research. Pediatric study plans: content of and process for submitting initial pediatric study plans and amended initial pediatric study plans. US Food and Drug Administration. 2020. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/pediatric-study-plans-content-and-process-submitting-initial-pediatric-study-plans-and-amended. Accessed 21 June 2023."},{"key":"2570_CR12","unstructured":"EMA. Paediatric investigation plans: questions and answers. European Medicines Agency. 2018. https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/paediatric-medicines\/paediatric-investigation-plans\/paediatric-investigation-plans-questions-answers. Accessed 21 June 2023."},{"key":"2570_CR13","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NHG. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303\u201332.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2570_CR14","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/jcph.1371","volume":"59","author":"I Mahmood","year":"2019","unstructured":"Mahmood I. Initiation of pediatric clinical trials for coagulation factors: application of pharmacokinetics and allometry to first-in-pediatric dose selection. J Clin Pharmacol. 2019;59:829\u201334.","journal-title":"J Clin Pharmacol"},{"key":"2570_CR15","unstructured":"FDA. and BeneFIX. US Food and Drug Administration. 20222. https:\/\/www.fda.gov\/vaccines-blood-biologics\/approved-blood-products\/benefix. Accessed 21 June 2023."},{"key":"2570_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1208\/ps040427","volume":"4","author":"U W\u00e4hlby","year":"2002","unstructured":"W\u00e4hlby U, Jonsson EN, Karlsson MO. Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS J. 2002;4:68\u201379.","journal-title":"AAPS J"},{"key":"2570_CR17","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1055\/s-0037-1615621","volume":"85","author":"GC White 2nd","year":"2001","unstructured":"White GC 2nd, Rosendaal F, Aledort LM, et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor\u00a0IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85:560.","journal-title":"Thromb Haemost"},{"key":"2570_CR18","unstructured":"Introduction to hemophilia. Stage ELearning. https:\/\/elearning.wfh.org\/elearning-centres\/hemophilia\/. Accessed 21 June 2023."},{"key":"2570_CR19","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3109\/08880018.2014.930768","volume":"31","author":"P Giordano","year":"2014","unstructured":"Giordano P, Lassandro G, Valente M, Molinari AC, Ieran\u00f2 P, Coppola A. Current management of the hemophilic child: a demanding interlocutor. Quality of life and adequate cost-efficacy analysis. Pediatric Hematol Oncol. 2014;31:687\u2013702.","journal-title":"Pediatric Hematol Oncol"},{"key":"2570_CR20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/antib9030040","volume":"9","author":"I Mahmood","year":"2020","unstructured":"Mahmood I. Prediction of clearance of monoclonal and polyclonal antibodies and non-antibody proteins in children: application of allometric scaling. Antibodies (Basel). 2020;9:40.","journal-title":"Antibodies (Basel)"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02570-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02570-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02570-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T15:17:15Z","timestamp":1692112635000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02570-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":20,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["2570"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02570-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2023,6,21]]},"assertion":[{"value":"2 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}